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Abstract
Background: Ionized calcium (Ca) and magnesium (Mg) compete as essential messengers to regulate cell proliferation and
inflammation. We hypothesized that inadequate Mg levels, perhaps relative to Ca levels (e.g. a high Ca/Mg ratio) are
associated with greater prostate cancer risk.
Study Design: In this biomarker sub-study of the Nashville Men’s Health Study (NMHS), we included 494 NMHS participants,
consisting of 98 high-grade (Gleason$7) and 100 low-grade cancer cases, 133 prostate intraepithelial neoplasia (PIN) cases,
and 163 controls without cancer or PIN at biopsy. Linear and logistic regression were used to determine associations
between blood Ca, Mg, and the Ca/Mg ratio across controls and case groups while adjusting for potential confounding
factors.
Results: Serum Mg levels were significantly lower, while the Ca/Mg ratio was significantly higher, among high-grade cases
vs. controls (p=0.04, p=0.01, respectively). Elevated Mg was significantly associated with a lower risk of high-grade prostate
cancer (OR=0.26 (0.09, 0.85)). An elevated Ca/Mg ratio was also associated with an increased risk of high-grade prostate
cancer (OR=2.81 (1.24, 6.36) adjusted for serum Ca and Mg). In contrast, blood Ca levels were not significantly associated
with prostate cancer or PIN.Mg, Ca, or Ca/Mg levels were not associated with low-grade cancer, PIN, PSA levels, prostate
volume, or BPH treatment.
Conclusion: Low blood Mg levels and a high Ca/Mg ratio were significantly associated with high-grade prostate cancer.
These findings suggest Mg affects prostate cancer risk perhaps through interacting with Ca.
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Introduction
Prostate cancer is the most common non-cutaneous malignancy
in Western societies and the second leading cause of cancer death
in men [1]. A number of prospective studies have investigated the
relationship between calcium and overall prostate cancer risk, with
decidedly mixed results [2–6]. Several studies also investigating the
relationship between calcium intake and the risk of aggressive or
clinically relevant prostate cancers have generated both null [4,6]
and positive results [7–13]. In contrast, two recent studies found
higher serum calcium levels associated with aggressive lesions or
fatal prostate cancer [14,15]. Blood calcium levels are tightly
regulated, and only moderately affected by dietary intake of
calcium and absorption rate [16]. Thus, one possible explanation
for the inconsistencies across study populations is that dietary
intake measures of calcium may not accurately reflect the blood
calcium concentration to which prostate tissue is exposed.
Magnesium is the second most abundant intracellular cation in
the body, involved with over 300 biological activities [17], and
calcium and magnesium levels in the body are jointly regulated
through a negative feedback system [16], and through competition
for intestinal absorption and renal reabsorption [18]. Calcium and
magnesium also compete for membrane binding sites within the
cell, and previous in vitro and in vivo studies indicate that
magnesium inhibits calcium activity or that magnesium deficiency
enhances the physiologic effects of calcium [17,19,20].
The 1999–2000 National Health and Nutrition Examination
Survey found 79% of U.S. adults have a magnesium intake below
the Recommended Dietary Allowance [21]. Magnesium deficien-
cy in Western societies has been linked to insulin resistance
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coronary heart disease [27], colorectal cancer [28], and colorectal
adenoma [29]. Similar to the relationships between obesity and
most chronic diseases, systemic inflammation may be a unifying
pathway by which magnesium deficiency contributes to such a
broad range of morbidity [19,30]. Chronic inflammation may also
play a key role in the progression from normal tissue to prostatic
intraepithelial neoplasia (PIN) and prostate cancer [31], and it is
also possible that the elevated inflammatory response associated
with magnesium deficiency is dependent on concurrent calcium
levels [19].
The purpose of this study is to investigate the association
between serum magnesium with prostatic intraepithelial neoplasia
(PIN), low-grade prostate cancer, and high-grade prostate cancer.
We further investigated the interaction between magnesium and
calcium levels on aggressive or high-grade prostate cancer risk,
hypothesizing that inadequate serum magnesium levels reflected
by a high serum ratio of calcium to magnesium will be associated
with more aggressive prostate cancer.
Materials and Methods
Study Population
The Nashville Men’s Health Study (NMHS) utilizes a multi-
centered, rapid-recruitment protocol to collect clinical, biological,
behavioral, and body measurement data from men scheduled for
diagnostic prostate biopsy. All participants provided written
informed consent in accordance with the Vanderbilt University
IRB. Men scheduled for a diagnostic prostate biopsy between
2002 and 2008 at a Vanderbilt University Medical Center
(Nashville, TN), the Tennessee Valley Veteran’s Administration
Hospital (Nashville, TN), or a large private urology practice in
Nashville, were approached for recruitment. Eligible participants
were 40 years of age or older and had no prior prostate cancer
diagnosis. Approximately 95% of eligible men approached for
recruitment agree to participate, and the study population
included 2,100 eligible consenting subjects. Pathology data were
analyzed from two labs, but over 90% of patients were diagnosed
at a large community urologic partnership with one on-site
pathologist. We have compared in a sub-sample of 60 men
pathology scoring at biopsy from pathology after gland removal
(the definitive staging) and found similar biopsy Gleason score
categories.
Biomarker Sub-Study
In 2009, a sub-study of 503 NMHS participants was developed
for translational investigations of promising biomarkers hypothe-
sized to be associated with prostate cancer risk. We included all
137 available PIN cases available to us at that time through
recruitment, and PIN cases served as the age index for frequency
matching. We then randomly selected from our available
recruitment 101 high-grade prostate cancer cases (Gleason=7(4+3
only), 8, 9, or 10) and 100 low-grade prostate cancer cases
(Gleason=6) such that the PIN, low-grade, and high-grade cases
had an age distribution between 50–80 years and had a similar age
distribution using 5-year age categories. We also randomly
selected 165 biopsy-negative controls using identical age criteria
from approximately 900 candidates, although we oversampled
controls less than age 55 through random selection to support the
analysis of younger men with fewer cancer outcomes.
Data Collection
Measures of body size and weight were collected by a trained
research staff member at the time of recruitment. Participants
wore a hospital gown or other light clothing, and did not wear
shoes. Chart review included age, race, PSA history, and prostate
needle-biopsy result (cancer, PIN, negative, or a suspicious,
atypical, or other lesion). Gleason scores at biopsy were also
ascertained for subjects diagnosed with cancer following pathology
review of the biopsy specimen. Prostate volume (cm
3) was
measured by transrectal ultrasound (TRUS) during the prostate
biopsy procedure. Family history of prostate cancer was
ascertained from the surgical chart and by a structured research
questionnaire administered to each participant upon recruitment.
As a part of the pre-biopsy clinic visit, all NMHS participants
are instructed to make a list of all current medications at home or
to bring their medications to this clinic visit. Prior to biopsy, the
surgeon reviews all survey responses with the participant to
confirm that the subject has been taking the listed drugs.
Additionally, the surgeon makes specific queries to the subject
for drugs such as aspirin or Warfarin that might affect bleeding or
clotting during the biopsy procedure. All prescription and non-
prescription drugs were abstracted from the medical record
following consent from the participant. Drug categories were
developed to represent men receiving treatment for cardiovascular
disease, diabetes, BPH, or taking a non-steroidal anti-inflamma-
tory agent. Drugs formulated as a combination of two or more
active drugs were classified by each of the component drugs.
Biomarker Assays
Serum concentration of magnesium and calcium were deter-
mined by standard analytic method on the Beckman DXC 800
chemistry analyzer provided by the Vanderbilt Pathology
Laboratory Services with an intra-assay coefficient of variation
of 2.0. Several biomarkers associated with obesity were also
analyzed. All study biomarker assays include a standard set of
blank and positive controls and were performed in a single batch
and blind to case-control status.
Data Analysis
Among 503 participants, we dropped these participants (1 high-
grade cancer, 1 PIN, 1 control) for missing magnesium levels; (1
control, 1 low-grade cancer, 1 PIN) for missing calcium levels; and
(1 PIN, 1 high-grade cancer) for missing both Mg and Ca. We also
dropped 1 PIN case with severe hypocalcemia (2.5 ng/ml). Thus,
the final analytic study population included 494 participants (99
high-grade cancer and 99 low-grade cancer, 133 PIN, and 163
negatives). Analyses that controlled for WHR were limited to 493
participants with WHR.
The current molecular sub-study was independently funded to
test our a priori hypothesis, as stated from our grant, that low serum
magnesium levels are associated with increased risk of PIN and
prostate cancer, perhaps more so among men with elevated
calcium levels. Thus, our primary analyses investigated the
associations between serum magnesium and calcium/magnesium
ratio and risk of PIN and prostate cancer, whereas all other
analyses were conducted to support the primary analysis or to
explore nature of our primary findings. Because we also proposed
the direction of the association in the a priori hypothesis, one-sided
tests were performed for primary hypotheses.
Prior to testing our primary hypothesis, preliminary analyses
compared mean magnesium and calcium levels across age
categories, demographics, obesity measures, PSA levels, prostate
volume, NSAID use, treatment for BPH, CVD, hypercholester-
olemia, or diabetes. The distributions of magnesium, calcium, and
the ratio of calcium to magnesium ratio (Ca/Mg) were
approximately normally distributed and therefore were not
transformed for analysis. Our primary analyses compared mean
Magnesium, Calcium and Prostate Cancer
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groups. We report mean values adjusted for WHR, diabetes
treatment, CVD treatment, and race in a linear model after
finding that these factors were significantly associated with either
calcium or magnesium levels, orCa/Mg (p,0.05). We also
adjusted for age to accommodate potential residual confounding
not addressed through the frequency matching of cases and
controls for the biomarker sub-study. Logistic regression was used
to calculate odds ratios (ORs) and 95% confidence intervals
summarizing the association between magnesium, calcium, or Ca/
Mg with each case outcome in separate models adjusting for age or
for age, WHR, race, and treatment for diabetes and CVD.
Magnesium, calcium, and Ca/Mg were scaled as continuous
variables or categorized at tertiles of the control-group distribu-
tion. Tests for interaction were determined by cross-product term
between magnesium or calcium and the covariates of interest in
the presence of each main-effect and other covariates.
Results
Controls, PIN cases, and cancer cases had similar distributions
for age, race, and family history of prostate cancer (Table 1).
Serum levels of magnesium, calcium, and Ca/Mg averaged
2.14 ng/ml, 9.72 ng/ml, and 4.58, respectively. Magnesium levels
were not significantly correlated with calcium levels overall
(r=20.06, p=0.17), or within controls (r=0.06, 0.48), or low-
grade (r=20.05, p=0.62) or high-grade (r=20.07, 0.52) cancer
cases.There was a significant but weak inverse correlation between
magnesium and calcium levels among PIN cases (r =20.20,
p=0.02).
Magnesium levels were significantly lower among non-white
participants, as well as participants being treated for diabetes or
CVD (Table 2). However, only 16 non-white subjects were being
treated for diabetes. Calcium and the Ca/Mg were also
significantly associated with treatment for diabetes, and the Ca/
Mg ratio was significantly lower among whites compared to non-
whites. Furthermore, serum calcium and the Ca/Mg ratio were
significantly higher with a higher WHR. In contrast, magnesium,
calcium, and Ca/Mg were not significantly associated with current
use of steroid reductase inhibitors and/or alpha blockers, PSA
levels, prostate size, BMI, or other factors considered. Thus, final
analytic models did not adjust for current use of steroid reductase
inhibitors and/or alpha blockers, PSA and prostate size, BMI, or
volume.
Magnesium levels were approximately 5% lower among high-
grade cancer cases compared to controls (p=0.04) or PIN cases
(p=0.03) after adjusting for age, WHR, race, and treatment for
diabetes and CVD (Table 3). Accordingly, the Ca/Mg ratio was
significantly higher among high-grade cases compared to controls
(p=0.01) and PIN cases (p=0.05). The Ca/Mg ratio was also
higher among high-grade cancer cases compared to low-grade
cases (p=0.05). In contrast, serum calcium levels were somewhat
higher among high-grade prostate cancer cases, but differences in
calcium levels between groups were not statistically significant.
Similarly, increasing magnesium levels were associated with a
lower likelihood of being diagnosed with high-grade prostate
cancer. For example, magnesium levels in the highest tertile were
associated with an approximate 48% reduction in risk (OR=0.52,
(0.26, 1.02; p-trend=0.04). This association became stronger after
additional control for calcium (OR=0.48 (0.24–0.96; p-
trend=0.03) (Table 4). While high-grade cancer was not
associated with calcium levels, the Ca/Mg ratio was associated
with an increasing trend for greater risk of high-grade prostate
cancer. Furthermore, Ca/Mg as a continuous variable was
significantly associated with high-grade disease (OR=2.81 (1.24,
6.36), adjusted for magnesium, calcium, and other covariates).
Table 5 summarizes the relationship between magnesium levels
and high-grade disease across calcium levels, and suggests that
higher magnesium levels may lower the risk of high-grade prostate
cancer among men with high calcium levels (OR=0.48 (0.23,
1.00)).
Discussion
We found serum magnesium levels, and the ratio of calcium-to-
magnesium (Ca/Mg), was significantly associated with high-grade
prostate cancer. Calcium levels alone, in contrast, were not
consistently associated with prostate cancer or PIN. Our analyses
Table 1. Study population description.
Controls PIN Low-Grade High-Grade
Factor mean sd mean sd mean sd mean sd
Age (yrs) 66.7 7.7 65.6 6.5 67.0 7.4 67.9 6.8
Level n % n % n % n %
50–54 10 6.2% 5 3.8% 7 7.0% 3 3.1%
55–59 20 12.4% 26 19.6% 9 9.0% 9 9.2%
60–64 31 19.1% 24 18.1% 15 15.2% 16 16.1%
65–69 34 20.9% 31 23.3% 28 28.3% 31 31.6%
70–74 36 22.1% 39 29.3% 20 20.2% 20 20.2%
75–79 32 19.6% 8 6.0% 20 20.2% 20 20.2%
Family history Yes 29 17.8% 28 21.0% 16 16.2% 13 13.1%
Unsure 84 51.5% 55 41.4% 59 59.6% 61 61.6%
No 50 30.7% 50 37.6% 24 24.2% 25 25.3%
Race/Ethnicity White 147 90.2% 120 90.2% 88 88.9% 88 88.9%
Black 15 9.2% 13 9.8% 10 10.1% 11 11.1%
Asian or Hispanic 1 0.6% 0 0% 1 1.0% 0 0%
doi:10.1371/journal.pone.0018237.t001
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effect that may be at least partially dependent on calcium levels
toward the pathogenesis for high-grade prostate cancer.
Table 2. Association between Mg, Ca, and Ca/Mg with study
population characteristics.
Factor Level n* Mg Ca Ca/Mg
Age (yrs) 50–54 25 2.25 9.63 4.30
55–59 64 2.12 9.88 4.73
60–64 86 2.17 9.80 4.56
65–69 124 2.16 9.71 4.59
70–74 115 2.12 9.67 4.61
75–79 80 2.14 9.65 4.54
P**= 0.19 0.43 0.16
Race/Ethnicity Non-white 51 2.03 9.82 4.88
White 443 2.16 9.71 4.55
P= ,0.01 0.36 ,0.01
Family History Yes 86 2.17 9.71 4.52
Unsure 259 2.13 9.72 4.64
No 149 2.18 9.74 4.53
P= 0.06 0.95 0.16
BMI (kg/m
2) 16–19 3 2.05 9.73 4.77
20–24 76 2.12 9.63 4.61
25–29 248 2.15 9.69 4.56
30–34 125 2.16 9.81 4.59
35–52 42 2.14 9.82 4.64
P= 0.69 0.51 0.93
Height (cm) 157–170 129 2.14 9.65 4.55
171–174 109 2.15 9.79 4.63
175–178 131 2.16 9.64 4.51
179–192 125 2.14 9.83 4.65
P= 0.94 0.14 0.32
Waist (cm) 73–97 127 2.16 9.61 4.51
98–104 120 2.14 9.64 4.57
105–111 123 2.15 9.82 4.63
112–145 123 2.15 9.83 4.63
P= 0.92 0.06 0.45
WHR 0.780–0.978 125 2.15 9.60 4.52
0.979–1.022 125 2.18 9.67 4.48
1.023–1.061 119 2.14 9.89 4.68
1.062–1.230 124 2.12 9.76 4.68
P= 0.22 0.04 0.03
PSA (ng/ml) 0.2–3.9 85 2.15 9.72 4.55
4.0–9.9 321 2.16 9.73 4.57
10.0–334 84 2.12 9.73 4.67
P= 0.43 0.97 0.38
Volume (mls) 10–9 190 2.13 9.71 4.62
40–59 161 2.17 9.75 4.54
60–27 127 2.15 9.74 4.60
P= 0.29 0.91 0.49
NSAIDs
(regular use)
Yes 225 2.16 9.79 4.60
No 269 2.14 9.67 4.57
P= 0.51 0.08 0.70
Treatment for
BPH Yes 143 2.15 9.69 4.57
Table 3. Adjusted Mean Mg (ng/ml), Ca (ng/ml), or Ca/Mg
Levels, PIN, and Prostate Cancer.
Mg (ng/ml) Ca (ng/ml) Ca/Mg
n Mean
95%
CI Mean
95%
CI Mean
95%
CI
Age-Adjusted
Negative-Control 163 2.16 2.13, 2.20 9.70 9.57,
9.82
4.52 4.42,
4.63
PIN 133 2.18 2.14, 2.22 9.73 9.59,
9.87
4.52 4.41,
4.64
Low-Grade cancer 99 2.14 2.10, 2.19 9.66 9.50,
9.82
4.57 4.44,
4.71
High-Grade cancer 98 2.09‘ 2.04, 2.13 9.82 9.66,
9.98
4.78‘‘ 4.65,
4.92
Fully-Adjusted*
Negative-Control 163 2.09 2.04, 2.13 9.81 9.64,
9.98
4.75 4.62,
4.89
PIN 133 2.09 2.04, 2.14 9.87 9.68,
10.06
4.79 4.64,
4.94
Low-Grade cancer 99 2.07 2.02, 2.13 9.76 9.56,
9.95
4.78 4.62,
4.94
High-Grade cancer 98 2.03** 1.97, 2.08 9.91 9.72,
10.10
4.96*** 4.81,
5.11
‘High-grade cancer vs. (negative-controls: p=0.01), (PIN: p,0.01), or (low-grade
cancer: p=0.09).
‘‘High-grade cancer vs. (negative-controls: p,0.01), (PIN: p,0.01), or (low-
grade cancer: p=0.03).
*Adjusted for age (continuous), treatment for diabetes (Yes/No), treatment for
CVD (Yes/No), WHR (categorized at quartiles), and race (white, non-white).
**High-grade cancer vs. (negative-controls: p=0.04), (PIN: p=0.03), or (low-
grade cancer: p=0.13).
***High-grade cancer vs. (negative-controls: p=0.01), (PIN: p=0.05), or (low-
grade cancer: p=0.05).
No other differences were significant at p,0.05.Additional adjustment for
family history did not change these results.
doi:10.1371/journal.pone.0018237.t003
Factor Level n* Mg Ca Ca/Mg
No 351 2.15 9.74 4.59
P= 0.99 0.57 0.79
CVD Yes 300 2.13 9.70 4.63
No 194 2.18 9.76 4.52
P= 0.02 0.42 0.07
Hyperlipidemia Yes 204 2.15 9.77 4.61
No 290 2.15 9.70 4.57
P= 0.88 0.25 0.57
Diabetes Yes 78 2.04 9.90 4.94
No 416 2.17 9.69 4.52
P= ,0.01 0.03 ,0.01
*missing values: waist (n=1), WHR (n=1), PSA (n=4), volume (n=16).
**p-value to test for one-way ANOVA testing for differences in Mg, Ca, or Ca/Mg
between levels of each factor.
doi:10.1371/journal.pone.0018237.t002
Table 2. Cont.
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messenger roles regulating cell cycle proliferation and apoptosis
[32–34]. Calcium consumption might also reduce the production
of 1,25-dihydroxyvitamin D (1,25(OH)2D; calcitriol), the hormon-
al form of vitamin D [35]. However, studies of dietary calcium
intake in relation to aggressive prostate cancer have produced
mixed results [2], with little evidence of an association in the
Melbourne Collaborative Cohort Study [6], the Calcium Polyp
Prevention Study [3], the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial [4], or a recent prospective analysis of
blood calcium levels [5]. In contrast, several prospective studies
have suggested that greater intake of calcium [2] or a higher level
of serum calcium [14,15] is associated with aggressive, poorly
differentiated, lesions or fatal prostate cancer. Our analysis may be
the first to suggest that the relationship between calcium and
prostate cancer depends, at least to some degree, on the counter-
effects of magnesium, and provides one possible explanation for
some inconsistency in the previous studies.
Magnesium plays an essential role in DNA repair, cell
differentiation and proliferation, apoptosis, and angiogenesis
[17,19,36]. Magnesium deficiency is also linked to the inflamma-
tory response [19] and oxidative stress [37], while magnesium
supplementation, in contrast, improves insulin sensitivity and
reduces insulin levels [23] [22]. Given the broad range of
biological functions dependent on magnesium, it is highly plausible
that magnesium deficiency may affect multiple pathways toward
tumorigenesis across the body. For example, a recent study found
mice transplanted with Lewis Lung Carcinoma and receiving a
low-Mg diet had a significant 70% reduction in primary tumor
growth, but also had a higher metastatic potential [38].
Interestingly, we found low serum Mg was only associated with
an increased risk of high-grade prostate cancer, but not PIN or
low-grade prostate cancer, perhaps consistent with the higher
metastatic potential found in the prior animal studies. Magnesium
acts as a physiologic antagonist to ionized calcium [17], and a low
ionized magnesium level may further potentate the activity of
ionized calcium [17]. We found the Ca/Mg ratio was associated
with high grade prostate cancer after adjusting for magnesium and
calcium levels, and there was a somewhat stronger, although not
significantly stronger, association between magnesium and high-
grade prostate cancer among men with higher serum calcium.
Thus, our data suggest that magnesium levels may influence the
progression of prostate lesions to a higher grade. Migration studies
further reveal a substantial increase in the incidence of advanced
prostate cancer as men move from Eastern Asia to the West
[29,39], while the age-specific prevalence of indolent and early-
stage prostate cancer lesions detected at autopsy are relatively
uniform across countries [40]. Magnesium intake is similar
between the East and West, however the ratio of dietary calcium
to magnesium intake is much higher (2.8) in the US population
than (1.6) in East Asia [29], perhaps contributing to international
differences in prostate cancer risk described above, as well as
colorectal cancer risk [29]. We found previously that the calcium/
magnesium intake ratio modified the association between calcium
intake and magnesium intake on the risk of colorectal adenoma
[29]. Similarly, we found in our current prostate cancer study that
African Americans had a significantly higher Ca/Mg serum ratio
than whites, and our findings provide a possible underlying
mechanism for the racial disparity in fatal prostate cancer.
There are several strengths to this analysis, including the
opportunity to evaluate the potential for detection biases related to
differences in PSA,prostate volume. Blood was collected prior to
diagnosis and treatment, and body size measures were ascertained
by trained staff. One concern is that the temporal relationship
between magnesium, or the calcium/magnesium ratio, and
carcinogenesis cannot be conclusively determined. Although we
cannot exclude the possibility that the alterations in levels of
magnesium and calcium are an effect rather than a cause of
prostate cancer, previous animal studies suggest that our
Table 4. Association between Mg, Ca, or Ca/Mg with PIN and
Prostate Cancer.
Scale
N
(Case/Ctl) OR 95% CI OR‘ 95% CI
PIN Mg
(ng/ml)
continuous 133/163 1.07 0.36, 3.21 1.03 0.33, 3.17
,2.1 30/43 1.0 ref 1.0 ref
2.1–2.3 58/62 1.26 0.69, 2.32 1.24 0.67, 2.29
.2.3 45/58 0.97 0.52, 1.82 0.95 0.50, 1.81
Ca
(ng/ml)
continuous 133/163 1.08 0.81, 1.45 1.08 0.80, 1.45
,9.2 37/54 1.0 ref 1.0 ref
9.2–9.9 47/49 1.31 0.72, 2.38 1.29 0.70, 2.35
.9.9 49/60 1.24 0.69,2.23 1.23 0.68, 2.21
Ca/Mg continuous 133/163 1.10 0.75, 1.61 1.13 0.53, 2.41
,4.17 40/52 1.0 ref 1.0 ref
4.17–4.67 47/55 1.16 0.65, 2.07 1.08 0.51, 2.30
.4.67 46/56 1.28 0.71, 2.32 1.46 0.48, 4.47
Low-
Grade
Mg
(ng/ml)
continuous 99/163 0.71 0.22, 2.31 0.58 0.17, 1.98
,2.1 30/43 1.0 ref 1.0 ref
2.1–2.3 33/62 0.79 0.41, 1.51 0.72 0.37, 1.41
.2.3 36/58 0.92 0.47, 1.81 0.81 0.40, 1.61
Ca
(ng/ml)
continuous 99/163 0.87 0.62, 1.22 0.89 0.63, 1.25
,9.2 23/54 1.0 ref 1.0 ref
9.2–9.9 47/49 2.32 1.20, 4.50 2.44 1.25, 4.77
.9.9 29/60 1.02 0.51, 2.03 1.07 0.53, 2.14
Ca/Mg continuous 99/163 1.05 0.69, 1.61 1.22 0.55, 2.71
,4.17 33/52 1.0 ref 1.0 ref
4.17–4.67 27/55 0.75 0.39, 1.45 0.71 0.30, 1.68
.4.67 39/56 1.00 0.53, 1.90 1.17 0.36, 3.77
High-
Grade
Mg
(ng/ml)
continuous 98/163 0.31 0.10, 0.97 0.26 0.09, 0.85
,2.1 38/43 1.0 ref 1.0 ref
2.1–2.3 37/62 0.73 0.40, 1.36 0.70 0.38, 1.30
.2.3 23/58 0.52 0.26, 1.02 0.48 0.24, 0.96
Ca
(ng/ml)
continuous 98/163 1.16 0.85, 1.59 1.19 0.86, 1.63
,9.2 29/54 1.0 ref 1.0 ref
9.2–9.9 36/49 1.43 0.75, 2.75 1.58 0.81, 3.06
.9.9 33/60 1.01 0.53, 1.95 1.04 0.54. 2.02
Ca/Mg continuous 98/163 1.68 1.11, 2.53 2.81 1.24, 6.36
,4.17 22/52 1.0 ref 1.0 ref
4.17–4.67 29/55 1.22 0.61, 2.41 1.12 0.48, 2.66
.4.67 47/56 1.84 0.94, 3.61 2.04 0.64, 6.58
Adjusted for age, treatment for diabetes, treatment for CVD, WHR, and race.
‘also adjusted for magnesium, calcium, or magnesium and calcium, as
appropriate.
doi:10.1371/journal.pone.0018237.t004
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prior studies in humans found lower levels of magnesium (thus,
higher serum calcium/magnesium ratio) lead to inflammation and
insulin resistance which have been linked to progression of
prostate cancer. In our study, we only found significant differences
between negative controls with high-grade cancer, but not PIN or
low-grade cancer. This argues that lower levels of magnesium (or
high calcium/magnesium ratio) are not simply a consequence of
cancer, but does not remove the possibility that high-grade cancer
in some way affects blood Mg levels. There is a somewhat higher
probability that high-grade prostate cancer has metastasized to the
bone, and bone provides a repository for circulating calcium and
magnesium. However, clinical chart review from 189 prostate
cancer cases from this study found that no evidence of metastatic
disease or lymph node involvement at diagnosis. Nevertheless,
prospective studies are warranted to confirm our novel findings.
Although men with prior BPH surgery were not eligible for this
analysis and we found no association between current BPH
treatment with Mg or Ca, we cannot eliminate the possibility that
a presumably small number of past finasteride user affected our
results. The difference in Ca/Mg serum ratio between whites and
African Americans needs to be interpreted with caution because
this was a secondary analysisbased on only 50 African American
participants.
Our finding indicates that higher blood magnesium levels are
associated with a lower risk of high-grade prostate cancer. The
lower ratio of calcium to magnesium was also associated with high-
grade prostate cancer, suggesting the interaction between
magnesium and calcium plays a role in the pathogenesis and
progression of this disease to a more clinically relevant phase.
These findings, if confirmed, may provide a new avenue for the
personalized prevention or adjuvant care of prostate cancer.
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